Previous studies have indicated that biomarkers associated with the efficacy of ICIs can be broadly categorized into two groups: those related to tumor neoantigen burden, such as MSI or high TMB [22, 23]; and those indicative of a T‐cell‐inflamed tumor microenvironment, including the expression of PD‐L1 on tumor and immune cells infiltration [24, 25, 26, 27]. This evidence concerns the gene CD274 and neoplasm.